News: PIQ Proteomics International Laboratories Launches PromarkerD In Spain Under Deal With Patia..., page-25

Have a look at Polynovo.
Current market cap of about $1.4 B and five years ago the market cap was nothing.
Their main burns product had sales of $9m last year with total revenue of $13m.
Arguably, the market for Promoarker D is significantly higher than for burns treatments .
PIQ needs actual sales and if using Promarker D becomes accepted practice for identification
of kidney problems then we know the potential is extremely high.
As an example, identifying Malaria in Tanzania is done by a simple pin prick to the finger test and it is about 83%
accurate and it is the go to test used.
Clearly, Promarker D is for a different market but it remains to be seen if it becomes accepted practice .